中文版 | English

在结果中检索

HFCAS OpenIR
（本次检索基于用户作品认领结果）

浏览/检索结果: 共33条，第1-10条 帮助

限定条件        
已选(0)清除 条数/页：   排序方式：
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang;  Li, Xi-xiang;  Wang, Bei-lei;  Ge, Juan;  Zou, Feng-ming;  Chen, Cheng;  Wang, Jun-jie;  Hu, Chen;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载：84/0  |  提交时间：2022/03/28
HER2  breast cancers  gastric cancers  irreversible inhibitor  drug resistance  
An overview of kinase downregulators and recent advances in discovery approaches 期刊论文
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 卷号: 6
作者:  Wang, Beilei;  Wu, Hong;  Hu, Chen;  Wang, Haizhen;  Liu, Jing;  Wang, Wenchao;  Liu, Qingsong
收藏  |  浏览/下载：68/0  |  提交时间：2022/01/25
Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia 期刊论文
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 卷号: 6
作者:  Hu, Chen;  Zou, Fengming;  Wang, Aoli;  Miao, Weili;  Liang, Qianmao;  Weisberg, Ellen L.;  Wang, Yinsheng;  Liu, Jing;  Wang, Wenchao;  Liu, Qingsong
收藏  |  浏览/下载：50/0  |  提交时间：2021/11/01
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML) 期刊论文
EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 卷号: 897
作者:  Lu, Tingting;  Cao, Jiangyan;  Zou, Fengming;  Li, Xixiang;  Wang, Aoli;  Wang, Wenliang;  Liang, Huamin;  Liu, Qingwang;  Hu, Chen;  Chen, Cheng;  Hu, Zhenquan;  Wang, Wenchao;  Li, Lili;  Ge, Jian;  Shen, Yang;  Ren, Tao;  Liu, Jing;  Xia, Ruixiang;  Liu, Qingsong
收藏  |  浏览/下载：58/0  |  提交时间：2021/04/26
BCR-ABL  ABL mutants  Chronic myeloid leukemia  Kinase inhibitor  Imatinib resistance  
Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia 期刊论文
HAEMATOLOGICA, 2021, 卷号: 106
作者:  Wang, Aoli;  Hu, Chen;  Chen, Cheng;  Liang, Xiaofei;  Wang, Beilei;  Zou, Fengming;  Yu, Kailin;  Li, Feng;  Liu, Qingwang;  Qi, Ziping;  Wang, Junjie;  Wang, Wenliang;  Wang, Li;  Weisberg, Ellen L.;  Wang, Wenchao;  Li, Lili;  Ge, Jian;  Xia, Ruixiang;  Liu, Jing;  Liu, Qingsong
收藏  |  浏览/下载：47/0  |  提交时间：2021/04/26
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia 期刊论文
EXPERIMENTAL CELL RESEARCH, 2020, 卷号: 393
作者:  Chen, Cheng;  Wang, Li;  Li, Lili;  Wang, Aoli;  Huang, Tao;  Hu, Jie;  Zhao, Ming;  Liu, Feiyang;  Qi, Shuang;  Hu, Chen;  Wang, Wenliang;  Liu, Jing;  Ge, Jian;  Xia, Ruixiang;  Wang, Wenchao;  Liu, Qingsong
收藏  |  浏览/下载：37/0  |  提交时间：2020/11/26
Acute myeloid leukemia (AML)  Drug response  Gene mutations  
Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52 期刊论文
ACTA PHARMACOLOGICA SINICA, 2020
作者:  Wang, Wen-liang;  Jiang, Zong-ru;  Hu, Chen;  Chen, Cheng;  Hu, Zhen-quan;  Wang, Ao-li;  Wang, Li;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载：56/0  |  提交时间：2020/11/26
PGK1  NG52  kinase inhibitor  Warburg effect  glioma  
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway 期刊论文
ACTA PHARMACOLOGICA SINICA, 2020
作者:  Chen, Cheng;  Cheng, Chuan-dong;  Wu, Hong;  Wang, Zuo-wei;  Wang, Li;  Jiang, Zong-ru;  Wang, Ao-li;  Hu, Chen;  Dong, Yong-fei;  Niu, Wan-xiang;  Qi, Shuang;  Qi, Zi-ping;  Liu, Jing;  Wang, Wen-chao;  Niu, Chao-shi;  Liu, Qing-song
浏览  |  Adobe PDF(3476Kb)  |  收藏  |  浏览/下载：91/34  |  提交时间：2020/11/26
glioblastoma  osimertinib  temozolamide  MAPK-signaling pathway  MNK  eukaryotic translation initiation factor 4E  
Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent 期刊论文
ACTA PHARMACEUTICA SINICA B, 2020, 卷号: 10
作者:  Jiang, Zongru;  Wang, Li;  Liu, Xuesong;  Chen, Cheng;  Wang, Beilei;  Wang, Wenliang;  Hu, Chen;  Yu, Kailin;  Qi, Ziping;  Liu, Qingwang;  Wang, Aoli;  Liu, Jing;  Hong, Guangchen;  Wang, Wenchao;  Liu, Qingsong
收藏  |  浏览/下载：50/0  |  提交时间：2020/11/26
Cancer  VEGFR2 kinase  Kinase inhibitor  Angiogenesis  Inhibitor selectivity  
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) 期刊论文
CANCER BIOLOGY & THERAPY, 2019, 卷号: 20, 期号: 6, 页码: 877-885
作者:  Wu, Jiaxin;  Wang, Aoli;  Li, Xixiang;  Chen, Cheng;  Qi, Ziping;  Hu, Chen;  Wang, Wenliang;  Wu, Hong;  Huang, Tao;  Zhao, Ming;  Wang, Wenchao;  Hu, Zhenquan;  Liu, Qingwang;  Wang, Beilei;  Wang, Li;  Li, Lili;  Ge, Jian;  Ren, Tao;  Xia, Ruixiang;  Liu, Jing
收藏  |  浏览/下载：50/0  |  提交时间：2019/11/27
BCR-ABL  PDGFR  chronic myeloid leukemia  kinase inhibitor